Evonik Corporation’s PERACLEAN® 22CW, a peracetic acid, has been proven to reduce exposure to harmful bacteria such as Salmonella and Campylobacter during initial processing steps while also exhibiting more long-term stability over competing products.
Results of a recent full-scale pilot study conducted by University of Arkansas at its Center for Food Safety and Department of Poultry Science and sponsored by Evonik, demonstrate that PERACLEAN® 22CW reduced Salmonella and Campylobacter during processing. For Salmonella, the Evonik product exhibited results that were numerically lower than the competitive products that were tested. The results for Campylobacter were even better with PERACLEAN® 22CW equal or better than competitive products in three of four tests. In one trial, PERACLEAN® 22CW completely eliminated Campylobacter.
“Food safety is the highest priority for consumers as well as poultry processors," said Florian Lyon, Director, Strategic Marketing & Business Development Active Oxygens – North America for Evonik. “PERACLEAN® 22CW gives poultry processors an environmentally friendly solution to better guard against foodborne illness.”
“PERACLEAN® 22CW’s longer shelf life versus competing products has been proven to produce stronger bactericidal results,” adds Bob Gec, Technical Product Manager, North America, Peracetic Acid for Evonik.
PERACLEAN® 22 CW, a peracetic acid, is an environmentally friendly, antimicrobial agent approved for use in a number of intervention points including both online and offline reprocessing spray, wash, rinse, chiller or scald, and other process water for whole or cut meat and poultry carcasses.
PERACLEAN® 22 CW is OMRI and Kosher certified and meets all USDA standards when used as directed for applications up to 2,000 ppm. PERACLEAN® 22 CW is also process-friendly and requires no rinsing, is non-foaming, and non-corrosive to stainless steel.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.